AGTR1 and polycystic ovary syndrome: However, due to their potential teratogenic, fetotoxic, and miscarriage-associated risks during pregnancy, ACE inhibitors and AT1R blockers are rarely used in the clinic in PCOS women of reproductive age (98–100).